Cabaletta Bio, Inc. CABA
Set alert
At close · Oct 30
After hours · Oct 30, 7:44 PM ET
- YTD
- -31.05%
- 1 year
- -38.87%
- Open
- 1.54
- Prev close
- 1.59
- Mkt cap
- 256.01M
- Vol
- 3.76M
- Avg vol
- 5.20M
- EPS
- -1.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.43
- High
- 1.59
- Forward P/E
- -0.98
- Beta
- 2.42
- Short ratio
- 4.26
- Inst. own
- 100.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.53
- 200-d avg
- 8.16
- 1y target
- 22.22
5D chart
Signals (57)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2:35 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:15 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 1:50 PM | 1 day ago |
| RSI: Oversold | Oct 30, 1:50 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:35 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:20 PM | 1 day ago |
| RSI: Oversold | Oct 30, 12:10 PM | 1 day ago |
| RSI: Oversold | Oct 30, 11:45 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| RSI: Oversold | Oct 28, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 5 days ago |
| RSI: Oversold | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 5 days ago |
| RSI: Oversold | Oct 26, 11:50 AM | 5 days ago |
News
2 weeks ago seekingalpha.com
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns
Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase…
3 weeks ago globenewswire.com
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
1 month ago seekingalpha.com
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
2 months ago benzinga.com
Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted…
2 months ago globenewswire.com
Cabaletta Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
-
2 months ago benzinga.com
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of…
2 months ago globenewswire.com
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
4 months ago seekingalpha.com
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing…
4 months ago seekingalpha.com
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
-
5 months ago benzinga.com
Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through…
5 months ago globenewswire.com
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through…
5 months ago zacks.com
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
5 months ago zacks.com
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
-
5 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
5 months ago seekingalpha.com
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in…
-
5 months ago benzinga.com
Cabaletta Bio Q1 EPS $(0.39), Inline
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same…
5 months ago globenewswire.com
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV study presented today at ASGCT 2026 Annual Meeting along with initial…
5 months ago globenewswire.com
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of…
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
6 months ago benzinga.com
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…
-
6 months ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
-
6 months ago benzinga.com
Cabaletta Prices Share Sale Of 51.73M Shares at $2.90 to Fund Autoimmune Therapy Development
Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for…
6 months ago globenewswire.com
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative…
6 months ago businesswire.com
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply…
6 months ago globenewswire.com
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial…
6 months ago globenewswire.com
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed…
-
6 months ago benzinga.com
Cabaletta Bio Doses First Two Patients Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET™ clinical…
6 months ago businesswire.com
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s (“Cabaletta Bio” or…
6 months ago benzinga.com
FGI Industries, Nouveau Monde Graphite And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29 cents per share beating estimates but sales missing. Stock down 7.8% in pre-market. Other stocks…
7 months ago benzinga.com
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.
-
7 months ago benzinga.com
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13
Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.
-
7 months ago benzinga.com
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16
Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.
-
7 months ago benzinga.com
Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of…
7 months ago globenewswire.com
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
9 months ago benzinga.com
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
-
9 months ago benzinga.com
Cabaletta Bio Announces 2026 Strategic Priorities To Advance Rese-Cel Toward 2027 BLA, Expand Automated Cellares Manufacturing, And Progress RESET Trials Across Autoimmune Diseases
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment…
12 months ago benzinga.com
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30
Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $15 to $30.
-
1 year ago benzinga.com
Cabaletta Bio Announces Clinical Data And Development Updates Across RESET-Myositis, RESET-SSc And RESET-SLE Trials Evaluating Rese-Cel
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
-
1 year ago benzinga.com
Cabaletta Bio Reports Initial Results For Rese-cel In Pemphigus Vulgaris Without Preconditioning; Shows Complete B Cell Depletion, Rapid Reduction In Autoantibodies And Near-complete Resolution Of Clinical Symptoms In Two Of Three Refractory Patients
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators…
-
1 year ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $15 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $15 price target.
1 year ago benzinga.com
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
-
1 year ago benzinga.com
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $2
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $3 to $2.